Esperion Therapeutics (ESPR) Invested Capital (2012 - 2026)

Esperion Therapeutics has reported Invested Capital for 15 years, with the latest figure at -$210.5 million in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital fell 73.56% year-over-year to -$210.5 million; the trailing twelve-month figure through Mar 2026 stood at -$210.5 million (down 73.56% YoY), and the FY2025 full-year result was -$204.7 million, up 29.91% from the prior year.
• Invested Capital for Q1 2026 stood at -$210.5 million, down from -$204.7 million in the prior quarter.
• The five-year high for Invested Capital was -$121.3 million in Q1 2025, with the low at -$410.0 million in Q3 2023.
• Historically, Invested Capital has averaged -$296.1 million across 5 years, with a median of -$294.3 million in 2024.
• Annual changes were most pronounced in 2025 — Invested Capital jumped 58.78% — and 2026, when it slumped 73.56%.
• Esperion Therapeutics' Invested Capital stood at -$323.8 million in 2022, then soared by 40.27% to -$193.4 million in 2023, then slumped by 51.0% to -$292.0 million in 2024, then grew by 29.91% to -$204.7 million in 2025, then fell by 2.87% to -$210.5 million in 2026.
• The last three Invested Capital figures came in at -$210.5 million (Q1 2026), -$204.7 million (Q4 2025), and -$396.5 million (Q3 2025), per Business Quant data.